|
Subsequent Events
|
3 Months Ended |
|---|---|
|
Mar. 31, 2015
|
|
| Subsequent Events [Abstract] | |
| Subsequent Events |
12. Subsequent events On April 6, 2015, the Company executed a product development agreement with RRD International, LLC (“RRD”), a clinical product development organization, which provides the Company with integrated and expert level strategic, clinical, medical, regulatory and operational management and execution of its CF-301 clinical program. In conjunction with the execution of the agreement, the Company issued 28,445 shares of its common stock to RRD for the initial $150,000 of services provided. |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. No definition available.
|